Emerging Infectious Disease Diagnostics Market Report 2025

This emerging infectious disease diagnostics market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The emerging infectious disease diagnostics market size has grown strongly in recent years. It will grow from $22.13 billion in 2024 to $24.34 billion in 2025 at a compound annual growth rate (CAGR) of 10%. The growth in the historic period can be attributed to increasing demand for point-of-care diagnostics, increasing prevalence of infectious diseases, increasing global population density, rising incidence of infectious diseases, and increasing healthcare expenditure.

The emerging infectious disease diagnostics market size is expected to see strong growth in the next few years. It will grow to $35.21 billion in 2029 at a compound annual growth rate (CAGR) of 9.7%. The growth in the forecast period can be attributed to the rising incidence of zoonotic diseases, significant growth in regulatory changes and support, development of universal vaccines, increasing focus on one health approach, and rising government support and funding. Major trends in the forecast period include technological advancements, next-generation sequencing (NGS), isothermal amplification techniques, telemedicine and remote diagnostics, and environmental pathogen monitoring.

The increasing incidence of zoonotic diseases is projected to drive the growth of the emerging infectious disease diagnostics market in the future. Zoonotic diseases are infections that can be transmitted from animals to humans and are caused by various pathogens, including bacteria, viruses, parasites, or fungi. The rise in zoonotic diseases is primarily attributed to heightened human-wildlife interactions, habitat destruction, and global travel, which facilitate the transmission of pathogens across species. Emerging infectious disease diagnostics play a crucial role in managing zoonotic diseases by enabling early detection and accurate identification of pathogens. This capability allows for prompt intervention, effective treatment, and improved containment of disease outbreaks, thus reducing transmission from animals to humans. For example, in February 2024, the 2022 Zoonotic Disease Report published by the State of West Virginia, a US-based government agency, noted that the number of reported Lyme disease cases increased to 2,449 in 2022, up from 1,788 cases in 2021. Therefore, the rising incidence of zoonotic diseases is driving the growth of the emerging infectious disease diagnostics market.

Leading companies in this market are focusing on technological advancements, such as molecular diagnostic platforms, to gain a competitive edge. These platforms utilize nucleic acid amplification techniques to detect pathogens with high sensitivity and specificity, enabling accurate and early diagnosis. For instance, in May 2022, Becton Dickinson and Company, a US-based medical equipment manufacturer, introduced the BD COR MX/PX System, a fully automated, high-throughput diagnostic platform. This system enhances laboratory efficiency by automating the entire molecular workflow, from sample processing to result delivery. Its initial assay, the BD CTGCTV2, detects three common non-viral sexually transmitted infections (STIs). The BD COR MX/PX System can process up to 1,700 specimens with onboard reagent and sample capacity, providing over seven hours of continuous operation and delivering up to 1,000 results in 24 hours, significantly reducing manual handling by lab technicians.

In August 2022, Bio-Rad Laboratories Inc., a US-based life science research and clinical diagnostics company, acquired Curiosity Diagnostics for $170 million. This acquisition is notable for Bio-Rad as it enhances their portfolio by integrating Curiosity Diagnostics' PCR|ONE platform, a rapid diagnostics system designed specifically for molecular diagnostics. Curiosity Diagnostics, based in Poland, specializes in molecular diagnostic systems for managing infectious diseases.

Major companies operating in the emerging infectious disease diagnostics market are Roche Diagnostics, Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers, Becton Dickinson and Company, Laboratory Corporation of America Holdings, Quest Diagnostics Incorporated, Agilent Technologies Inc., Hologic Inc., Illumina Inc., bioMérieux SA, QuidelOrtho Corporation, Bio-Rad Laboratories, Inc., Qiagen N.V., DiaSorin S.p.A., Randox Laboratories Ltd., Meridian Bioscience Inc., Sekisui Diagnostics LLC, Copan Diagnostics, Co-Diagnostics Inc., T2 Biosystems Inc.

North America was the largest region in the emerging infectious disease diagnostics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the emerging infectious disease diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the emerging infectious disease diagnostics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Emerging infectious disease diagnostics involve advanced techniques and tools used to identify new or re-emerging infectious diseases caused by pathogens such as viruses, bacteria, or parasites. These diagnostics utilize cutting-edge technologies, including molecular testing, genomics, and rapid assays, to detect infections with speed and accuracy, thereby enhancing public health responses. They play a vital role in monitoring and controlling outbreaks and in the development of targeted treatments and vaccines.

The primary types of infections addressed by emerging infectious disease diagnostics include viral, bacterial, fungal, and others. Viral infections are diseases caused by viruses, which are minute pathogens that reproduce inside the host’s cells. These include respiratory infections, gastrointestinal infections, and sexually transmitted infections (STIs). The technologies used for detection include polymerase chain reaction (PCR), isothermal nucleic acid amplification technology (INAAT), next-generation sequencing (NGS), and immunodiagnostics, among others. Diagnostics can be applied in laboratory testing and point-of-care testing settings and are utilized by various end-users such as hospitals, clinics, diagnostic laboratories, and others.

The emerging infectious disease diagnostics market research report is one of a series of new reports that provides emerging infectious disease diagnostics market statistics, including emerging infectious disease diagnostics industry global market size, regional shares, competitors with a emerging infectious disease diagnostics market share, detailed emerging infectious disease diagnostics market segments, market trends and opportunities, and any further data you may need to thrive in the emerging infectious disease diagnostics industry. This emerging infectious disease diagnostics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The emerging infectious disease diagnostics market consists of revenues earned by entities by providing services such as laboratory testing, diagnostic tool development, clinical interpretation of test results, surveillance and reporting, and the provision of telehealth consultations. The market value includes the value of related goods sold by the service provider or included within the service offering. The emerging infectious disease diagnostic market also includes sales of rapid test kits, polymerase chain reaction (PCR) machines, molecular diagnostic assays, sequencing platforms, point-of-care diagnostic devices, and biosensors. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.